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Objective. We have compared the two situations: if we had continued with our treatment until wow and when we have changed
the treatment, two years ago.
Material and methods. We have used these material and methods: the planner XIO (VERSION 4.5 and 4.62 of CMS), accelerators
linear siemens, model artiste (MLC 160 sheets, 05 cm nominal width) and IMRT of step and shoot. The proposed method consists
of carrying out a comparison of two planning prostates. We recalculate IMRTS’s planning of the year 2010 in 2012, with many
experience acquired during these years, have managed to diminish the number of segments, the time of radiation and all this
without losing the quality of the treatment. To improve the ﬁnal results, we modiﬁed the parameters during the calculation. To
improve our ﬁnal result, we modiﬁed the parameters with the aim to reduce segments without the histogram.
Results. The modiﬁcations of the parameters in the calculation have considerably reduced the 269 segments in the treatment
from 2010 to 69 segments in 2012.
Conclusion. The analysis of the registered information has shown a reduction in the number of segments without altering the
treatment dosimetric quality.
http://dx.doi.org/10.1016/j.rpor.2013.03.515
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Background. In the treatment of early prostate cancer, clinical data suggest that higher radiation doses delivered to the bulb of
penis and proximal penile structures correlates with higher rates of post-radiation impotence. Is of special interest irradiation
techniques that reduce the dose in the tissues.
Objectives. Review sexual impotence in patients treated with radical technical VMAT-Rapid Arc (IGRT/CBCT daily) and relationship
with the radiation doses to the penile bulb.
Methods. We conducted this study in a consecutive series of 16 patients diagnosed for localized prostate cancer (low risk and
intermediate risk without androgen deprivation) treated between May 2011 and December 2012. All patients were treated with
volumetric modulated arc therapy (VMAT). Dose prescription was 70Gy to a planning target volume (2.5Gy/fraction). The Impo-
tence Status was assessed pretreatment and at the last follow-up. Was measured at the median dose to the bulb (MD) for all
patients, being located by CT fusion with MRI in all patients. The dose limiting established for performing dosimetry was DM to
bulb < of 47.5Gy.
Results. 16 patients were included. 13 of the 16 patients were potent before the treatment. 3 were impotent and were excluded.
Mean follow-up was 11 months (4–16). Only 2 patients of 13 were impotent post-radiation, without other known causes. MD to
the bulb was 2642.8 cGy on the potent men and 5069.5 cGy on the impotent men.
Conclusions. VMAT-Rapid Arc provides treatment plans with high conformity is an efﬁcient radiotherapy technique to increase
dose in target volumesanddecrease irradiationdose in organs at risk. The technique is very important tomaximizeposttreatment
potency. Our data conﬁrm this.
http://dx.doi.org/10.1016/j.rpor.2013.03.516
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Introduction. Recommended treatment guidelines for localized prostate cancer by most urologists and radiation oncologists in
Spain, include surgery or radiotherapy. However, there are patients who refuse treatment or are not considered candidates
for local treatment due to comorbidities or advanced age, being treated with androgen deprivation monotherapy. Objective. To
retrospectively analyze our experience in patients diagnosed with localized castrate resistant prostate cancer who underwent
external beam radiotherapy.
Method. Between March 2006 and July 2011, 13 patients attended our center with a diagnosis of castrate resistant prostate cancer.
Staging workup was negative. No patient received chemotherapy previously. Initially 2, 4 and 6 patients were classiﬁed as low,
intermediate and high risk, respectively, according to risk groups by D’Amico. All patients received 3D radiation therapy and
continued androgen deprivation during the treatment.
Results. From 2006 to 2011 we treated 13 patients. Median PSA level before radiation therapy was 4.8ng/ml (2.6–64ng/ml). Median
Total radiation dose was 72Gy (66–78Gy). With a median follow-up of 49 months (12–55 months), PSA response after treatment
occurred in 8 patients (67%) with a median time to biochemical progression of 18.6 months. Distal failure was the most frequent
clinical failure. Any local failure was detected.
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Conclusion. Radiation treatment achieved an excellent local control rate in this patient’s subgroup. This treatment must be
considered as a valid option to treat these patients, despite the high incidence of distal failure.
http://dx.doi.org/10.1016/j.rpor.2013.03.517
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Objective. Our objective is to determine the duration of clinical and radiological stabilization after PSA progression in chemother-
apy naïve mCRPC patients treated with AA, as well as analyzing its safety proﬁle in our series.
Material and methods. Retrospective analysis approved by our institution’s Ethical Committee of Clinical Investigation. 14 patients
with mCRPC who had not received prior chemotherapy in treatment with AA (1 g/24h) and prednisone (5mg/12h) have been
studied. Statistical analysis has been carried out with SPSS® version 15.
Results. Patient mean age is 75 (range 52–85), with 50% of patients having a pre-AA ECOG score ≥2. Mean treatment duration
time has been 9 months (2–12 months). PSA response, deﬁned as a 50% or higher decrease from pretreatment baseline PSA, was
observed in 75% of the patients. With a 12 month follow-up, we ﬁnd that: only 1 patient has progressed (deﬁned as clinical, radio-
logical and PSA progression). 7 patients (50%) present clinical, radiological and PSA stability. 7 patients present PSA progression,
of which 3 also associate radiological progression, 1 clinical progression and 1 with both clinical and radiological progression as
well. Treatment was suspended in 3 patients (21.4%), 1 due to PSA and radiological progression, 1 due to PSA, radiological and
clinical progression and 1 exitus due to tumor progression. In terms of treatment tolerance, no patients have presented neither
clinical nor hematological toxicity.
Conclusion. Treatment with AA in mCPCR chemo naïve patients is safe and very well tolerated, which is important considering
that most of the patients in our series were elderly patients, with average performance status, and in most cases not suitable for
other treatment options. In current clinical practice, evaluation for treatment response in mCRPC is changing, and PSA should
no longer be considered a reliable tumor marker in these patients. In our series, we have observed clinical and/or radiological
progression in only a small number of patients, normally months after PSA progression.
http://dx.doi.org/10.1016/j.rpor.2013.03.518
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Purpose. Determine biochemical response, control and disease free survival in a series of patients with long follow-up, treated
with salvage external beam radiation therapy (EBRT), the standard treatment for biochemical recurrence (BR), after radical
prostatectomy (RP).
Material and methods. Between July 2002 and July 2010, 78 patients were treated with salvage EBRT in our center. After EBRT,
BR has been deﬁned as a value of PSA≥0.2ng/ml. All patients were treated with 3D conformed EBRT. Median dose was 66Gy
(46–74Gy). 33 patients (42.3%) received hormone therapy (HT). All patients have been followed up by PSA and digital rectal
examination.
Results. The mean age was 65.6 years (SD 5.65). The preoperative PSA was <10, 10–20 or >20 in 54.3%, 35.7% and 10% respectively.
57.7% of patients were pT2, pT3a 17.9%, pT3b 15.4% and pTx 9%. The margins were negative in 43 patients (55.8%), and positive
in 31 (40.3%). 38 patients (62.3%) had a Gleason score ≤6, 13 Gleason 7 (21.3%) and 10 Gleason 8–10 (16.4%). The median PSA pre-
EBRT was 1.17ng/ml (range 0.12–19). The median post surgical PSA was 0.09ng/ml (range 0–4.2). The median follow-up was 46
months (range 22–116). Although biochemical response was seen in 63 patients (80.7%), the overall 5-year biochemical disease-
free survival rate was 55%. Multivariate analysis showed that ECOG (p=0.01) and post surgical PSA (p=0.03) were signiﬁcant
covariates predicting for bNED. Interval from surgery to BR, Gleason score, extracapsular extension, lymphovascular invasion,
perineural extension or surgical margin involvement were not associated with BR.
